ProQR Therapeutics N.V.
ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines. ProQR develops therapies built on its Axiomer RNA editing platform, which is designed to address genetic disorders with unmet medical needs. Its current work centers on discovering and developing novel therapeutic candidates for severe rare diseases, with particular attention to inherited conditions and other genetic targets. The company operates in the biotechnology and healthcare sectors, where RNA medicine is an important area of research because it aims to modify disease-related genetic messages rather than conventional protein targets. ProQR Therapeutics N.V. serves as a specialized participant in the broader life sciences market, supporting research, clinical development, and potential commercialization pathways for next-generation genetic therapies. Headquartered in Leiden, the Netherlands, the company also maintains a presence in Cambridge, Massachusetts.
$1.31
-$0.14 (-9.66%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-273.14% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 15.9% YoY. Margins deteriorated 112.0pp alongside, both lines moving the wrong way.
ROIC dropped from -28.85% to -40.12%, capital efficiency is deteriorating. Negative free cash flow of -€54M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€18M
▼ -15.9% YoY
Net Income (TTM)
-€42M
▼ -51.9% YoY
Op. Margin
-233.37%
▼ -112.0pp YoY
ROIC
-40.12%
▼ -11.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€50M
▼ -42.3% YoY
Op. Cash Flow (TTM)
-€49M
▼ -45.1% YoY
Net Debt
-€76M
Net Cash Position
Cash & Equiv.
€92M
3Y CAGR: +64.2%
Continue Research
Is ProQR Therapeutics (PRQR) overvalued?
ProQR Therapeutics (PRQR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, ProQR Therapeutics scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is ProQR Therapeutics a high-quality business?+
ProQR Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -233.4% operating margin and a -40.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is ProQR Therapeutics a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh PRQR's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.